Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial | Synapse
March 1, 2026Open Access
Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome: a post hoc analysis of a phase 2 clinical trial
Key Points
To evaluate the effectiveness of serology as an early diagnostic tool for hemolytic uremic syndrome in pediatric patients.
Conducted a post hoc analysis of a phase 2 clinical trial.
Examined pediatric patients diagnosed with hemolytic uremic syndrome.
Utilized serological testing to assess diagnosis accuracy.
Serology demonstrated a strong predictive value for diagnosing hemolytic uremic syndrome.
Early detection through serology may improve management outcomes in affected children.
Abstract
This study was registered with ClinicalTrials.gov as NCT05569746.